Jan L. C. Loeffen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jan L. C. Loeffen has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Marijn A. Vermeulen
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
2 shared publications - Roland P. Kuiper
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
2 shared publications A. Buijs
Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands
1 shared publication- Alina Maria Hartmann
Medical Department II, Hematology and Oncology University Medical Center Schleswig‐Holstein, Campus Kiel Kiel Germany
1 shared publication - Auke Beishuizen
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
1 shared publication B. Rikhof
University Medical Centre Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 23 March 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (5) , 1067-1071
KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage
- 23 March 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (5) , 1067-1071
Open AccessKMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage
- Open Access
NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.
Open AccessNOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.
- Open Access
- 3 April 2021
- Published by Springer Nature in Familial Cancer
- Vol. 20 (4) , 349-354
Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma
We describe a case of a boy with neurodevelopmental delay and a diffuse large B-cell lymphoma (DLBCL) in whom we discovered a germline de novo 2p16.3 deletion including MSH6 and part of the FBXO11 gene. A causative role for MSH6 in cancer development was excluded based on tumor characteristics. The constitutional FBXO11 deletion explains the neurodevelopmental delay in the patient. The FBXO11 protein is involved in BCL-6 ubiquitination and BCL-6 is required for the germinal center reaction resulting in B cell differentiation. Somatic loss of function alterations of FBXO11 result in BCL-6 overexpression which is a known driver in DLBCL. We therefore consider that a causative relationship between the germline FBXO11 deletion and the development of DLBCL in this boy is conceivable.
- 3 April 2021
- Published by Springer Nature in Familial Cancer
- Vol. 20 (4) , 349-354
Open AccessConstitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma
We describe a case of a boy with neurodevelopmental delay and a diffuse large B-cell lymphoma (DLBCL) in whom we discovered a germline de novo 2p16.3 deletion including MSH6 and part of the FBXO11 gene. A causative role for MSH6 in cancer development was excluded based on tumor characteristics. The constitutional FBXO11 deletion explains the neurodevelopmental delay in the patient. The FBXO11 protein is involved in BCL-6 ubiquitination and BCL-6 is required for the germinal center reaction resulting in B cell differentiation. Somatic loss of function alterations of FBXO11 result in BCL-6 overexpression which is a known driver in DLBCL. We therefore consider that a causative relationship between the germline FBXO11 deletion and the development of DLBCL in this boy is conceivable.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 10514
Age as a prognostic factor for outcome in patients (pts) with rhabdomyosarcoma (RMS)
10514 Background: RMS mainly affects children and adolescents and is rarely seen in adults. Survival of children with RMS increased dramatically during the last three decades because of the introduction of multiagent chemotherapy in clinical trials (5-yrs overall survival (OS) 73% nonmetastatic vs 24% metastatic disease). By contrast, the scarce data on adult RMS indicate a dismal outcome (reported 5- yrs OS 21–44%). The question is whether this is due to a more advanced stage at diagnosis and/or different histologic subtypes. Methods: Data were collected from RMS pts diagnosed in three Dutch University Medical Centres during 1977–2005. The influence of the prognostic factors on OS were analysed with Cox regression analysis. The estimated survival probabilities were calculated using the Kaplan-Meier with log-rank score. A p-value <0.05 was considered significant. Results: Data from 170 pts were successfully retrieved. Median age at diagnosis was 10 years (range 0–75 yrs). Five-yrs OS in pts <16 yrs was 63.2% versus 34.3% in pts ≥16 yrs (p<0.001). Age as a continuous variable significantly influenced OS in univariate and multivariate analysis (p=0.016 and p= 0.026 resp.). Five-yrs OS in the main histologic groups was highest for nonmetastatic Embryonal RMS (ERMS, 68.2%), followed by nonmetastatic Alveolair RMS (ARMS, 40.0%), and was worst in metastatic disease (11.5%). Unfavorable histologic subtypes were correlated with a higher age; median age ERMS 7.0 years, ARMS 16.0 (correlation coefficients 0.358, p<0.001) In ERMS, metastatic disease at presentation was correlated with higher age (p=0.005). In nonmetastatic ERMS (n=74) univariate and multivariate prognostic factors for OS were age (p=0.002 and p=0.023), IRSG Clinical Group (p=0.030 and p=0.005) and the use of chemotherapy (p<0.001 and p<0.001). Conclusions: Our study indicates that age as a continuous variable is of prognostic significance on survival in all RMS patients as well as in the main subgroup with nonmetastatic ERMS. Increasing age was correlated with advanced stage of disease in ERMS. Whether different biologic behaviour and/or a treatment effects contribute as well is subject of further study. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 10514
Age as a prognostic factor for outcome in patients (pts) with rhabdomyosarcoma (RMS)
10514 Background: RMS mainly affects children and adolescents and is rarely seen in adults. Survival of children with RMS increased dramatically during the last three decades because of the introduction of multiagent chemotherapy in clinical trials (5-yrs overall survival (OS) 73% nonmetastatic vs 24% metastatic disease). By contrast, the scarce data on adult RMS indicate a dismal outcome (reported 5- yrs OS 21–44%). The question is whether this is due to a more advanced stage at diagnosis and/or different histologic subtypes. Methods: Data were collected from RMS pts diagnosed in three Dutch University Medical Centres during 1977–2005. The influence of the prognostic factors on OS were analysed with Cox regression analysis. The estimated survival probabilities were calculated using the Kaplan-Meier with log-rank score. A p-value <0.05 was considered significant. Results: Data from 170 pts were successfully retrieved. Median age at diagnosis was 10 years (range 0–75 yrs). Five-yrs OS in pts <16 yrs was 63.2% versus 34.3% in pts ≥16 yrs (p<0.001). Age as a continuous variable significantly influenced OS in univariate and multivariate analysis (p=0.016 and p= 0.026 resp.). Five-yrs OS in the main histologic groups was highest for nonmetastatic Embryonal RMS (ERMS, 68.2%), followed by nonmetastatic Alveolair RMS (ARMS, 40.0%), and was worst in metastatic disease (11.5%). Unfavorable histologic subtypes were correlated with a higher age; median age ERMS 7.0 years, ARMS 16.0 (correlation coefficients 0.358, p<0.001) In ERMS, metastatic disease at presentation was correlated with higher age (p=0.005). In nonmetastatic ERMS (n=74) univariate and multivariate prognostic factors for OS were age (p=0.002 and p=0.023), IRSG Clinical Group (p=0.030 and p=0.005) and the use of chemotherapy (p<0.001 and p<0.001). Conclusions: Our study indicates that age as a continuous variable is of prognostic significance on survival in all RMS patients as well as in the main subgroup with nonmetastatic ERMS. Increasing age was correlated with advanced stage of disease in ERMS. Whether different biologic behaviour and/or a treatment effects contribute as well is subject of further study. No significant financial relationships to disclose.
- 2 September 1998
- Published by Springer Nature in Human Genetics
- Vol. 103 (2) , 245-250
Molecular characterization and mutational analysis of the human B17 subunit of the mitochondrial respiratory chain complex I
Bovine NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain consists of about 36 nuclear-encoded subunits. We review the current knowledge of the 15 human complex I subunits cloned so far, and report the 598-bp cDNA sequence, the chromosomal localization and the tissue expression of an additional subunit, the B17 subunit. The cDNA open reading frame of B17 comprises 387 bp and encodes a protein of 128 amino acids (calculated M r 15.5 kDa). There is 82.7% and 78.1% homology, respectively, at the cDNA and amino acid level with the bovine counterpart. The gene of the B17 subunit has been mapped to chromosome 2. Multiple-tissue dot-blots showed ubiquitous expression of the mRNA with relatively higher expression in tissues known for their high energy demand. Of these, kidney showed the highest expression. Mutational analysis of the subunit revealed no mutations or polymorphisms in 20 patients with isolated enzymatic complex I deficiency in cultured skin fibroblasts.
- 2 September 1998
- Published by Springer Nature in Human Genetics
- Vol. 103 (2) , 245-250
Molecular characterization and mutational analysis of the human B17 subunit of the mitochondrial respiratory chain complex I
Bovine NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain consists of about 36 nuclear-encoded subunits. We review the current knowledge of the 15 human complex I subunits cloned so far, and report the 598-bp cDNA sequence, the chromosomal localization and the tissue expression of an additional subunit, the B17 subunit. The cDNA open reading frame of B17 comprises 387 bp and encodes a protein of 128 amino acids (calculated M r 15.5 kDa). There is 82.7% and 78.1% homology, respectively, at the cDNA and amino acid level with the bovine counterpart. The gene of the B17 subunit has been mapped to chromosome 2. Multiple-tissue dot-blots showed ubiquitous expression of the mRNA with relatively higher expression in tissues known for their high energy demand. Of these, kidney showed the highest expression. Mutational analysis of the subunit revealed no mutations or polymorphisms in 20 patients with isolated enzymatic complex I deficiency in cultured skin fibroblasts.